These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22104015)

  • 1. Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial.
    Chrispijn M; Drenth JP
    Trials; 2011 Nov; 12():246. PubMed ID: 22104015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
    J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy for polycystic liver disease.
    Khan S; Dennison A; Garcea G
    Ann R Coll Surg Engl; 2016 Jan; 98(1):18-23. PubMed ID: 26688394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
    Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
    BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin analogues for treatment of polycystic liver disease.
    Gevers TJ; Drenth JP
    Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus.
    Friedman SL
    J Hepatol; 2013 Jul; 59(1):1-2. PubMed ID: 23583274
    [No Abstract]   [Full Text] [Related]  

  • 7. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
    Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
    Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
    Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP
    Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.
    Hogan MC; Masyuk T; Bergstralh E; Li B; Kremers WK; Vaughan LE; Ihrke A; Severson AL; Irazabal MV; Glockner J; LaRusso NF; Torres VE
    Mayo Clin Proc; 2015 Aug; 90(8):1030-7. PubMed ID: 26166166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
    van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
    Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term outcome of patients with polycystic liver disease treated with lanreotide.
    Chrispijn M; Nevens F; Gevers TJ; Vanslembrouck R; van Oijen MG; Coudyzer W; Hoffmann AL; Dekker HM; de Man RA; van Keimpema L; Drenth JP
    Aliment Pharmacol Ther; 2012 Jan; 35(2):266-74. PubMed ID: 22111942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
    Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
    J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
    Pisani A; Sabbatini M; Imbriaco M; Riccio E; Rubis N; Prinster A; Perna A; Liuzzi R; Spinelli L; Santangelo M; Remuzzi G; Ruggenenti P;
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1022-1030.e4. PubMed ID: 26844873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
    Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
    Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease.
    Temmerman F; Chen F; Libbrecht L; Vander Elst I; Windmolders P; Feng Y; Ni Y; De Smedt H; Nevens F; van Pelt J
    World J Gastroenterol; 2017 Aug; 23(30):5499-5507. PubMed ID: 28852309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.
    Caroli A; Antiga L; Cafaro M; Fasolini G; Remuzzi A; Remuzzi G; Ruggenenti P
    Clin J Am Soc Nephrol; 2010 May; 5(5):783-9. PubMed ID: 20185596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
    Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
    van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
    Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.